表紙:CDC7キナーゼ阻害剤:世界の臨床試験と市場機会 (2024年)

CDC7キナーゼ阻害剤:世界の臨床試験と市場機会 (2024年)

Global CDC7 Kinase Inhibitors Clinical Trials & Market Opportunity Insight 2024

出版日: | 発行: KuicK Research | ページ情報: 英文 60 Pages | 納期: 即日から翌営業日

価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.55円

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

CDC7キナーゼ阻害剤:世界の臨床試験と市場機会 (2024年)
出版日: 2023年11月01日
発行: KuicK Research
ページ情報: 英文 60 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次







第1章 CDC7キナーゼ阻害剤:イントロダクション

第2章 世界のCDC7キナーゼ阻害剤市場と臨床動向:適応症別

  • 白血病
  • 結腸直腸癌
  • 膵臓癌

第3章 世界のCDC7阻害剤市場の展望

  • 現在の市場の見通し
  • 将来の市場機会

第4章 CDC7キナーゼ阻害剤市場の動向:地域別

  • 中国
  • 日本
  • 英国
  • 米国

第5章 世界のCDC7プロテインキナーゼ阻害剤の臨床試験の概要

  • 国別
  • 適応症
  • フェーズ
  • 治療クラス

第6章 世界のCDC7プロテインキナーゼ阻害剤の臨床パイプライン:企業・適応症・フェーズ別

  • フェーズI
  • フェーズI/II

第7章 世界のCDC7キナーゼ阻害剤市場:市場力学

  • 市場促進要因
  • 市場の課題

第8章 競合情勢

  • Carna Biosciences
  • Chia Tai Tianqing Pharmaceutical Group
  • Eli Lilly
  • Memorial Sloan-Kettering Cancer Center
  • Schrodinger

List of Figures

  • Figure 1-1: CDC7 Kinase Inhibitor - Mechanism of Action
  • Figure 1-2: Comparison of CDC7 Inhibitors With Conventional Methods
  • Figure 1-3: CDC7 Inhibitor Development
  • Figure 2-1: LBS-007 Phase I/II Study - Initiation & Completion Year
  • Figure 2-2: Schrodinger Drug Discovery Approach
  • Figure 2-3: SGR-2921 Phase I Study - Initiation & Completion Year
  • Figure 2-4: TAK-931 Phase II Trials Commencement
  • Figure 2-5: Ongoing CDC7 Inhibitors Candidates - Mode Of Action
  • Figure 2-6: LY3143921 hydrate Phase I Study - Initiation & Completion Year
  • Figure 2-7: TQB3824 Phase I Study - Initiation & Completion Year
  • Figure 2-8: CDC7 Inhibitor For The Treatment Of Pancreatic Cancer
  • Figure 3-1: Global CDC7 Inhibitor - Current Ongoing Candidates In Trials
  • Figure 3-2: Global CDC7 Inhibitors Market - Future Aspects
  • Figure 4-1: Candidates Developed By Nerviano Medical Science
  • Figure 4-2: Aspects For The Inclining Growth Of CDC7 Inhibitors In China
  • Figure 4-3: AS-0141: Mechanism Of Action
  • Figure 4-4: Timeline Of AS-0141
  • Figure 4-5: Ongoing Research Conducted By Cancer Research Horizon
  • Figure 4-6: US - Cancer Incidences & Deaths, 2023
  • Figure 5-1: Global - CDC7 Protein Kinase Inhibitors Clinical Trials by Country (Numbers), 2023 & 2024
  • Figure 5-2: Global - CDC7 Protein Kinase Inhibitors Clinical Trials by Indication (Numbers), 2023 & 2024
  • Figure 5-3: Global - CDC7 Protein Kinase Inhibitors Clinical Trials by Phase (Numbers), 2023 & 2024
  • Figure 5-4: Global - CDC7 Protein Kinase Inhibitors Clinical Trials by Therapy Class (Numbers), 2023 & 2024
  • Figure 7-1: Global - CDC7 Inhibitor Market Drivers
  • Figure 7-2: Global - CDC7 Inhibitor Market Challenges

List of Tables

  • Table 2-1: Leukemia Cancer - CDC7 Kinase Inhibitor Ongoing Clinical Trials
  • Table 2-2: Colorectal Cancer - CDC7 Kinase Inhibitor Ongoing Clinical Trials
  • Table 2-3: Pancreatic Cancer - CDC7 Kinase Inhibitor Ongoing Clinical Trials
  • Table 4-1: China - CDC7 Kinase Inhibitor Ongoing Preclinical & Clinical Trials
  • Table 4-2: Japan - CDC7 Kinase Inhibitor Ongoing Clinical Trials
  • Table 4-3: UK - CDC7 Kinase Inhibitor Ongoing Clinical Trials

“Global CDC7 Kinase Inhibitors Clinical Trials & Market Opportunity Insight 2024” Report Highlights:

  • Global CDC7 Kinase Inhibitors Clinical Pipeline By Company, Indication & Phase
  • Highest Clinical Phase: Phase-I/II
  • US Dominating Global CDC7 Kinase Inhibitors Clinical Trials
  • Global CDC7 Inhibitors Market Current & Future Outlook
  • CDC7 Kinase Inhibitors Development Trends by Country
  • Competitive Landscape

Kinase proteins are targets of upmost importance in the realm of cancer therapeutics because of their ubiquitous roles in numerous cell processes. Research on kinases has spanned several decades, and in the process, a large number of kinases have been identified. One of these, discovered in the early 1970s, is the cell division cycle 7-related protein kinase, or the CDC7 kinase protein that is encoded by the CDC7 gene. Similar to other kinase proteins, CDC7 is needed for several cell processes, including replication, which has brought it into the limelight as another targetable protein for the development of cancer chemotherapies. Despite years of studies, researchers are still trying to understand the function and therapeutic potential of CDC7; however, a couple pharmaceutical companies are already making strides in the pharmaceutical market with their CDC7-inhibiting candidates in development and clinical evaluation.

CDC7 is a serine-threonine kinase. Its significance in the replication process was initially demonstrated using mouse embryonic stem cells, where DNA synthesis was inhibited in the absence of CDC7, resulting in the halting of the S phase at the G2-M DNA damage checkpoint to prevent mitosis with the damaged or incomplete DNA. CDC7 is therefore essential for the initiation of DNA replication process, making it a potential target for various therapeutic applications. CDC7 kinase functions in collaboration with tits regulatory subunit DBF4, forming the CDC7-DBF4 complex. This complex helps regulate the formation of the DNA replication origins, ensuring proper DNA replication and cell division.

One of the most promising aspects of CDC7 kinase is its potential as a cancer drug target. The uncontrolled proliferation of cancer cells often involves dysregulation of DNA replication, and CDC7 kinase is often overexpressed in various cancer types. Inhibition of CDC7 kinase can disrupt the replication process, leading to DNA damage and ultimately, cell death. As a result, targeting CDC7 kinase holds great promise in halting the progression of cancer. Traditional cancer therapies, such as chemotherapy and radiation, target rapidly dividing cells. In contrast, CDC7 kinase inhibitors focus on disrupting DNA replication process, offering a more specific and potentially less toxic approach.

Beyond cancer, CDC7 kinase is also gaining attention for its role in treating inflammatory and viral diseases. Inflammatory diseases often involve excessive cell proliferation, and the modulation of CDC7 kinase can potentially reduce this proliferation, mitigating the inflammatory response. Additionally, some viruses, particularly DNA viruses, reply on host cell DNA replication machinery for their own replication. Moreover, in a recently conducted study, it was shown that certain viruses, like Avibirnavirus, use the CDC7 to phosphorylate the VP3, enhancing the replication ability of the virus. By inhibiting CDC7 kinase, it may be possible to thwart viral replication, offering a new approach in antiviral therapies.

Inhibition of CDC7 offers potential benefits over other cancer therapies. The CDC7 kinase is involved in the DNA replication initiation, and inhibiting it is expected to have minimal off-target interactions, compared to other broadly targeted therapies. In addition, combining CDC7 kinase inhibitors with existing cancer chemotherapies has shown potential for enhanced efficacy in research studies. The combination of these therapies may provide a comprehensive solution to cancer treatment, addressing the heterogeneity of cancer cells. The overexpression of CDC7 kinase in specific cancer types allows for a personalized approach to treatment. So, patients with CDC7 kinase overexpression could benefit significantly from tailored therapies.

Pharmaceutical companies have recognized the potential of CDC7 kinase and are actively developing inhibitors for this target, with a few clinical trials. As clinical trials progress, the future of CDC7 kinase as a cancer drug target, anti-inflammatory target, and antiviral tool is becoming increasingly promising. The continued research and development in this field hold the potential to revolutionize cancer therapy, inflammatory disease treatment and antiviral strategies.

CDC7 kinase is developing as an intriguing player in the pharmaceutical sector, with substantial potential in the treatment of cancer, inflammatory processes, and viral diseases. Its specificity, synergy with existing therapies, and personalized treatment options make it a compelling choice for researchers and clinicians alike. As pharmaceutical companies invest in the development of CDC7 kinase inhibitors, the coming years look bright for this remarkable protein kinase, paving the way for innovative and effective therapeutic options.

Table of Contents

1. Brief Introduction To CDC7 Kinase Inhibitors

  • 1.1. Overview
  • 1.2. History & Emergence of CDC7 Kinase Inhibitors

2. Global CDC7 Kinase Inhibitors Market & Clinical Trends by Indications

  • 2.1. Leukemia
  • 2.2. Colorectal Cancer
  • 2.3. Pancreatic Cancer

3. Global CDC7 Inhibitors Market Outlook

  • 3.1. Current Market Outlook
  • 3.2. Future Market Opportunity

4. CDC7 Kinase Inhibitors Market Trend By Region

  • 4.1. China
  • 4.2. Japan
  • 4.3. UK
  • 4.4. US

5. Global CDC7 Protein Kinase Inhibitors Clinical Trials Overview

  • 5.1. By Country
  • 5.2. Indication
  • 5.3. Phase
  • 5.4. Therapy Class

6. Global CDC7 Protein Kinase Inhibitors Clinical Pipeline By Company, Indication & Phase

  • 6.1. Phase-I
  • 6.2. Phase-I/II

7. Global CDC7 Kinase Inhibitor Market Dynamics

  • 7.1. Market Drivers
  • 7.2. Market Challenges

8. Competitive Landscape

  • 8.1. Carna Biosciences
  • 8.2. Chia Tai Tianqing Pharmaceutical Group
  • 8.3. Eli Lilly
  • 8.4. Memorial Sloan-Kettering Cancer Center
  • 8.5. Schrodinger